EXPLORING THE THERAPEUTIC POTENTIAL OF LOW-DOSE COLCHICINE IN CORONARY ARTERY DISEASE: AN IN-DEPTH ANALYSIS OF INFLAMMATION, SAFETY, AND CLINICAL EFFECTIVENESS

VARSHITHA SRINIVAS; SWATHY SURESH

doi:10.22159/ijpps.2024v16i5.50574

Authors

VARSHITHA SRINIVAS Department of Pharmacy Practice, Institute of Pharmacy, PES University, Bangalore-560100, India https://orcid.org/0009-0008-9631-9935
SWATHY SURESH Department of Pharmacy Practice, Institute of Pharmacy, PES University, Bangalore-560100, India https://orcid.org/0009-0001-5066-9752

DOI:

https://doi.org/10.22159/ijpps.2024v16i5.50574

Keywords:

Coronary artery disease, low-dose colchicine, Inflammation, Cardiovascular events, Pathophysiology, Biomarkers

Abstract

Coronary Artery Disease (CAD) is a prevalent cardiovascular illness that is a primary cause of morbidity and mortality globally. It is distinguished by the constriction or blockage of the coronary arteries, which limits blood circulation to the heart. Inflammation is a driving force in the pathophysiology of CAD. Colchicine is an anti-inflammatory medication that has lately been studied for its potential application in the treatment of CAD. Its multimodal method of action has sparked interest due to its ability to treat inflammation and lower the concentration of critical inflammatory biomarkers. Clinical evidence validates the safe and effective use of Colchicine in CAD. Several recommendations advocate the use of colchicine in the secondary prevention of CAD. This article discusses the use of low-dose colchicine in CAD, its function in inflammation, as well as its safety and therapeutic effectiveness.

Downloads

Download data is not yet available.

References

Shembade SH, Tadakhe SV, Kore AP. Molecular modeling, synthesis, and antiproliferative evaluation of new isoxazole ring linked by Schiff bases and azo bond. Int J Pharm Pharm Res. 2023;26(3):196-213.

Coronary artery disease |cdc.gov. Centers for disease control and prevention; 2021. Available from: https://www.cdc.gov/heartdisease/coronary_ad.htm.

Shahjehan RD, Bhutta BS. Coronary Artery Disease. In: StatPearls; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564304 [Last accessed on 05 Apr 2024]

Martinez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015 Aug 24;4(8):e002128. doi: 10.1161/JAHA.115.002128, PMID 26304941, PMCID PMC4599469.

Montarello NJ, Singh K, Sinhal A, Wong DTL, Alcock R, Rajendran S. Assessing the impact of colchicine on coronary plaque phenotype after myocardial infarction with optical coherence tomography: rationale and design of the COCOMO-ACS study. Cardiovasc Drugs Ther. 2022 Dec;36(6):1175-86. doi: 10.1007/s10557-021-07240-9, PMID 34432196, PMCID PMC8384919.

Frąk W, Wojtasinska A, Lisinska W, Młynarska E, Franczyk B, Rysz J. Pathophysiology of cardiovascular diseases: new insights into molecular mechanisms of atherosclerosis, arterial hypertension, and coronary artery disease. Biomedicines. 2022 Aug 10;10(8):1938. doi: 10.3390/biomedicines10081938, PMID 36009488, PMCID PMC9405799.

Pencina MJ, Navar AM, Wojdyla D, Sanchez RJ, Khan I, Elassal J. Quantifying importance of major risk factors for coronary heart disease. Circulation. 2019 Mar 26;139(13):1603-11. doi: 10.1161/circulationaha.117.031855, PMID 30586759.

Brown JC, Gerhardt TE, Kwon E. Risk factors for coronary artery disease. StatPearls; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554410.

Shao C, Wang J, Tian J, Tang YD. Coronary artery disease: from mechanism to clinical practice. Adv Exp Med Biol. 2020;1177:1-36. doi: 10.1007/978-981-15-2517-9_1, PMID 32246442.

Ambrose JA, Singh M. Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Rep. 2015 Jan 14;7:8. doi: 10.12703/P7-08, PMID 25705391, PMCID PMC4311268.

Medina Leyte DJ, Zepeda Garcia O, Dominguez Perez M, Gonzalez Garrido A, Villarreal Molina T, Jacobo Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021 Apr 8;22(8):3850. doi: 10.3390/ijms22083850, PMID 33917744, PMCID PMC8068178.

Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005 Jan 25;111(3):363-8. doi: 10.1161/01.CIR.0000153339.27064.14, PMID 15668353.

Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 1993;22Suppl 4:S1-14. doi: 10.1097/00005344-199322004-00002, PMID 7523767.

Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003 Oct 28;108(17):2054-9. doi: 10.1161/01.CIR.0000089191.72957.ED, PMID 14581384.

Justyn M, Yulianti T, Wilar G. Long-term covid-19 effect to endothelial damage trough extrinsic apoptosis led to cardiovascular disease progression: an update review. Int J App Pharm. 2023;15(6):60-8. doi: 10.22159/ijap.2023v15i6.48889.

Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007 Mar 13;115(10):1285-95. doi: 10.1161/circulationaha.106.652859, PMID 17353456.

Hermida N, Balligand JL. Low-density lipoprotein-cholesterol-induced endothelial dysfunction and oxidative stress: the role of statins. Antioxid Redox Signal. 2014 Mar 10;20(8):1216-37. doi: 10.1089/ars.2013.5537, PMID 23924077.

Mundi S, Massaro M, Scoditti E, Carluccio MA, van Hinsbergh VWM, Iruela-Arispe ML. Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. Cardiovasc Res. 2018 Jan 1;114(1):35-52. doi: 10.1093/cvr/cvx226, PMID 29228169, PMCID PMC7729208.

Jebari Benslaiman S, Galicia Garcia U, Larrea Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022 Mar 20;23(6):3346. doi: 10.3390/ijms23063346, PMID 35328769, PMCID PMC8954705.

Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal. 2010 Jul 1;13(1):39-75. doi: 10.1089/ars.2009.2733, PMID 19888833, PMCID PMC2877120.

Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron. 2006;37(3):208-22. doi: 10.1016/j.micron.2005.10.007, PMID 16360317.

Gordon E, Schimmel L, Frye M. The importance of mechanical forces for in vitro endothelial cell biology. Front Physiol. 2020 Jun 18;11:684. doi: 10.3389/fphys.2020.00684, PMID 32625119, PMCID PMC7314997.

De Paoli F, Staels B, Chinetti Gbaguidi G. Macrophage phenotypes and their modulation in atherosclerosis. Circ J. 2014;78(8):1775-81. doi: 10.1253/circj.cj-14-0621, PMID 24998279.

Kumar V, Abbas AK, Aster JC. Robbins and cotran pathologic basis of disease. 10th ed. W. B. Saunders Company; 2014.

Roubille F, Kritikou E, Busseuil D, Barrere Lemaire S, Tardif JC. Colchicine: an old wine in a new bottle? Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):14-23. doi: 10.2174/1871523011312010004, PMID 23286287.

Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, Sackett DL. Colchicine: an ancient drug with novel applications. Br J Dermatol. 2018 Feb;178(2):350-6. doi: 10.1111/bjd.15896, PMID 28832953, PMCID PMC5812812.

Lodoco (colchicine) tablets-food and drug administration; 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/215727Orig1s000ltr.pdf [Last accessed on 21 Oct 2023]

Tong DC, Quinn S, Nasis A, Hiew C, Roberts Thomson P, Adams H. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020 Nov 17;142(20):1890-900. doi: 10.1161/circulationaha.120.050771, PMID 32862667.

Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019 Dec 26;381(26):2497-505. doi: 10.1056/NEJMoa1912388, PMID 31733140.

Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des. 2012;18(11):1478-93. doi: 10.2174/138161212799504731, PMID 22364132.

Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015 Jul;21(7):677-87. doi: 10.1038/nm.3893. PMID 26121197, PMCID PMC4519035.

Pamukcu B, Lip GY, Shantsila E. The nuclear factor-kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res. 2011 Aug;128(2):117-23. doi: 10.1016/j.thromres.2011.03.025, PMID 21636112.

Fiolet ATL, Silvis MJM, Opstal TSJ, Bax WA, van der Horst FAL, Mosterd A. Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. Plos One. 2020 Aug 31;15(8):e0237665. doi: 10.1371/journal.pone.0237665, PMID 32866166, PMCID PMC7458326.

Han K, Lu Q, Zhu WJ, Wang TZ, Du Y, Bai L. Correlations of degree of coronary artery stenosis with blood lipid, CRP, Hcy, GGT, SCD36 and fibrinogen levels in elderly patients with coronary heart disease. Eur Rev Med Pharmacol Sci. 2019 Nov;23(21):9582-9. doi: 10.26355/eurrev_201911_19453, PMID 31773710.

Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the stability (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial. J Am Heart Assoc. 2017 Oct 24;6(10):e005077. doi: 10.1161/JAHA.116.005077, PMID 29066452, PMCID PMC5721818.

Yamamoto E, Sugiyama S, Hirata Y, Tokitsu T, Tabata N, Fujisue K. Prognostic significance of circulating leukocyte subtype counts in patients with coronary artery disease. Atherosclerosis. 2016 Dec;255:210-6. doi: 10.1016/j.atherosclerosis.2016.08.033, PMID 27612676.

Opstal TSJ, Nidorf SM, Fiolet ATL, Eikelboom JW, Mosterd A, Bax WA. Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial. Int J Cardiol. 2023 Feb 1;372:1-5. doi: 10.1016/j.ijcard.2022.12.026, PMID 36529304.

Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007 Mar 15;99(6):805-7. doi: 10.1016/j.amjcard.2006.10.039, PMID 17350370.

Center for Drug Evaluation and Research. Colchicine (marketed as Colcrys) information, U.S. Food and Drug Administration; 2009. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/colchicine-marketed-colcrys-information [Last accessed on 21 Oct 2023]

Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996 Mar;100(3):290-8. doi: 10.1016/s0002-9343(97)89487-9, PMID 8629674.

Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021 Jul 21;42(28):2765-75. doi: 10.1093/eurheartj/ehab115. Erratum in: Eur heart J. 2021 May 23, PMID 33769515.

Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG. Colchicine in cardiovascular disease: in-depth review. Circulation. 2022 Jan 4;145(1):61-78. doi: 10.1161/circulationaha.121.056171, PMID 34965168, PMCID PMC8726640.

Akrami M, Izadpanah P, Bazrafshan M, Hatamipour U, Nouraein N, Drissi HB. Effects of colchicine on major adverse cardiac events in next 6 mo period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovasc Disord. 2021 Dec 7;21(1):583. doi: 10.1186/s12872-021-02393-9, PMID 34876021, PMCID PMC8650300.

Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-10. doi: 10.1016/j.jacc.2012.10.027, PMID 23265346.

Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020 Nov 5;383(19):1838-47. doi: 10.1056/NEJMoa2021372, PMID 32865380.

Yuan B, Meng X, Wang A, Niu S, Xie X, Jing J. Effect of different doses of colchicine on high sensitivity C-reactive protein in patients with acute minor stroke or transient ischemic attack: a pilot randomized controlled trial. Eur J Pharm Sci. 2022 Nov 1;178:106288. doi: 10.1016/j.ejps.2022.106288, PMID 36041708.

Kelly P, Weimar C, Lemmens R, Murphy S, Purroy F, Arsovska AP, O'Donnell M, Sandercock P, Tanne D, Tsivgoulis G, Walsh C, Williams D, Zedde M, Price CI. Colchicine for prevention of vascular inflammation in non-cardio embolic stroke (convince)-study protocol for a randomised controlled trial. Eur Stroke J. 2021 Jun;6(2):222-8. doi: 10.1177/2396987320972566, PMID 34414298, PMCID PMC8370082.

Colchicine for prevention of vascular inflammation in non-cardio embolic stroke (convince) ClinicalTrials.gov. Available from: https://clinicaltrials.gov/study/NCT02898610#contacts-and-locations [Last accessed on 05 Apr 2024]

Colchicine and spironolactone in patients with MI/Synergy Stent Registry-Full Text View; 2023. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03048825 [Last accessed on 21 Oct 2023]

Abrantes AM, Nogueira Garcia B, Alves M, Teixeira Passos D, Brito D, Pinto FJ. Low dose colchicine in coronary artery disease-systematic review and meta-analysis. Circ Rep 2021;3(8):457-64. doi: 10.1253/circrep.CR-21-0065, PMID 34414335.

Nelson K, Fuster V, Ridker PM. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2023;82(7):648-60. doi: 10.1016/j.jacc.2023.05.055, PMID 37558377.